Single Domain Antibodies: Unlocking the Potential of Targeted Therapeutics

Antibodies are an essential immune system component and play a vital role in disease diagnosis and treatment. In recent years, breakthroughs in the development of single-domain antibodies (sdAbs) have opened new possibilities in biotechnology and therapeutic applications.

These small antibodies are derived from the variable domains (VHH) of camelid heavy-chain-only antibodies found in certain species, such as alpacas and llamas. They offer a unique combination of advantages over traditional full-length antibodies, making them an attractive solution for various applications. To learn more about Single Domain Antibodies, click here.

Benefits of Single Domain Antibodies

  1. Improved Tissue Penetration: The small size of sdAbs makes them ideal for penetrating dense tissues and reaching their target site. This opens new possibilities for treating various diseases and previously challenging conditions with full-length antibodies.
  2. Increased Stability: The reduced size of sdAbs makes them more resistant to degradation, making them more stable in the body and longer-lasting than full-length antibodies. With a longer shelf life than traditional antibodies, they are ideal for use in long-term experiments, as well as for transportation and storage.
  3. Reduced Toxicity: The small size and reduced complexity of sdAbs also reduces the risk of off-target effects and toxicity, making them safer for patients.
  4. Lower Production Costs: sdAbs can be produced at a large scale cost-effectively.
  5. Breakthroughs in Research, Diagnostics, and Therapeutics: sdAbs have the potential to create advances in a variety of sectors, including cancer research, medicine development, and other life-saving therapies, due to their features.

Single domain antibodies offer more benefits than conventional antibodies such as enhanced tissue penetration, high affinity and specificity, and lot-to-lot consistency.

Maximize your Research Potential with ProSci Custom Antibody Services

ProSci offers a range of services for developing and producing single domain antibodies. Our state-of-the-art facilities and advanced technologies ensure the highest quality and consistency of our sdAbs, making them ideal for a wide range of applications. ProSci’s extensive 25-year experience in antibody development and production sets us apart, with 10+ years of experience in the field of single domain antibodies. Our process:

  • Immunization
  • PBMC Isolation
  • Library construction
    • Unique methodologies developed and employed to deliver highly diverse libraries
  • Panning & Screening
    • Panning against Naïve & Non-naïve libraries available
    • Direct ELISA screening for positive binders
  • Selection and Sequencing
    • Sequencing of up to 50 positive binders
    • Production of final clones
    • Sequences of binders provided
  • Production
    • Expression and purification yielding 0.5- 5.0mg of functional antibody

The custom antibody team at ProSci has expertise in developing and producing antibodies utilizing phage display or B cell cloning. Cutting-edge techniques allow us to construct a highly diverse library while offering panning solid or in-solution to uncover the most native epitopes. Our unique and validated processes result in increased specificity and improved binding capabilities.

We provide customized solutions for your single domain antibody needs at every stage, from immunization to large-scale production.

Single domain antibodies offer a unique combination of advantages over traditional full-length antibodies, making them an innovative solution for various research applications. If you’re looking for a reliable partner throughout all project stages, look no further than ProSci. ProSci’s expertise and advanced technologies provide a complete solution for the production and development of sdAbs, unlocking the full potential of your research.

Contact us to discuss your next project!

References